Rare disease biotech Aldexa Therapeutics files for a $20 million IPO

By
A A A

Aldexa Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, filed on Monday with the SEC to raise up to $20 million in an initial public offering. The Burlington, MA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. Aldexa Therapeutics initially filed confidentially on December 4, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

11,885,997
  • $27.665 ▼ 12.34%
8,989,448
  • $8.20 ▲ 2.24%
8,095,137
  • $100.4649 ▼ 0.06%
6,444,668
  • $15.49 ▲ 0.26%
5,675,311
  • $5.1971 ▲ 13.72%
4,598,051
  • $2.709 ▼ 3.59%
4,522,287
  • $11.285 ▼ 2.88%
4,172,395
  • $12.58 ▲ 8.54%
As of 8/20/2014, 09:58 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com